Pipeline Watch: Phase III Starts With VX-445, Reproxalap And AVXS-101
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Finance Watch: Investors Go Nuts For NASH As Madrigal Raises $300m, Galmed Skyrockets
Public Company Edition: Madrigal and Galmed shares more than doubled after reporting what were viewed as positive results in mid-stage NASH studies, with Madrigal going on to raise $300m on the back of the data. Not all is well for publicly traded firms, however, as Advaxis and Flex Pharma reveal layoffs.
Pipeline Watch: Phase III Readouts In Alopecia Areata, Cervical Dysplasia, Anaphylaxis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Merck KGaA's Diversified Business Model Proves Its Worth During Pandemic
Germany’s Merck KGaA rapidly expanded its life sciences services business to support the manufacture of COVID-19 vaccines during 2020, and also expects cancer and multiple sclerosis products to fuel its sales growth in coming years.
Need a specific report? 1000+ reports available
Buy Reports